Email updates

Keep up to date with the latest news and content from WJSO and BioMed Central.

Open Access Research

Differential expression of p42.3 in low- and high-grade gliomas

Weiqing Wan1, Xiaoqing Xu2, Guijun Jia1, Wenmei Li2, Junmei Wang3, Tong Ren1, Zhen Wu1, Junting Zhang1, Liwei Zhang1* and Youyong Lu2*

Author Affiliations

1 Department of Neurosurgery, Beijing Tiantan Hospital Capital Medical University, No.6 Tiantan Xili, Dongcheng District, 100050 Beijing, People’s Republic of China

2 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital/Institute, No. 52 Fucheng Road, Haidian District, 100142 Beijing, People’s Republic of China

3 Neuro-Pathology Department, Beijing Neurosurgical Institute, No.6 Tiantan Xili, Dongcheng District, 100050 Beijing, People’s Republic of China

For all author emails, please log on.

World Journal of Surgical Oncology 2014, 12:185  doi:10.1186/1477-7819-12-185

Published: 14 June 2014

Abstract

Background

Malignant gliomas are the most common form of primary malignant brain tumor. It has recently been suggested that genetic changes are involved in the progression of malignant gliomas. In previous studies, a novel gene, p42.3, was characterized as a tumor-specific gene that encodes a mitosis phase–dependent expression protein which is expressed in gastric cancer, but not in matched normal tissues.

Methods

In a series of 200 human brain gliomas and 13 normal tissues, we performed RT-PCR and mRNA in situ hybridization for analysis of p42.3 gene expression in gliomas, including astrocytoma (grade 2), oligoastrocytomas (grade 2), anaplastic oligoastrocytomas (grade 3), glioblastomas (grade 4) and normal tissues. Also, the mRNA expression was detected in gliomas by in situ hybridization. After producing polyclonal antibody to p42.3, we further tested p42.3 protein expression in astrocytomas and glioblastomas by immunohistochemistry and Western blot analysis.

Results

Our results demonstrated that overexpression of the p42.3 gene is detected in gliomas, but not in normal brain tissues. Importantly, p42.3 mRNA expression is correlated with the pathological features of gliomas. In addition, p42.3 protein is expressed in both the cytoplasm and the nucleus in astrocytomas, whereas this protein appeared in the cytoplasm in glioblastomas.

Conclusions

These results indicate that p42.3 might be involved in carcinogenesis as a potential molecular marker for malignant gliomas.

Keywords:
Brain; Expression; Glioma; p42.3